ArticleJournal of inflammation research2025
The Association Between Phenotypic Age and Primary Loss of Response to Biologic Agent in Patients with Crohn's Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Loss of response (LOR) to biological agents is challenging in Crohn's disease (CD) therapy. Identifying and predicting factors associated with therapeutic responses enables proactive intervention in high-risk LOR populations, such as adjusting therapeutic intensity or initiating second-line agents earlier, to avoid ineffective treatment and improve clinical outcomes. A few studies have also shown that biological age may be associated with treatment responses. This study aimed to show the association between phenotypic age, a type of biological age, and the primary loss of response to biological agents in patients with CD. Methods: This retrospective study included 94 CD patients, with 81 followed-up at the eighth week and 76 at the twelfth week in our institution. LOR was defined as biochemical remission (fecal calprotectin level < 250 μg/g or a reduction of > 50% from baseline levels). The phenotypic age was calculated based on a series of clinical biomarkers. Multivariate regression analysis was used to determine the association between phenotypic age and the LOR. The receiver operating characteristic curve (ROC) was used to show the performance of biological age in predicting the 8-week and 12-week LOR. Results: 33 patients had LOR at 8 weeks and 34 patients had LOR at 12 weeks. Patients with LOR had a higher phenotypic age and age gap than those with response (p < 0.001). Multivariable regression analyses further showed that phenotypic age and age gap were associated with LOR (8-week LOR, odds ratio (OR) = 1.18, 95% confidence interval (CI):1.07-1.32 and OR = 0.84, 0.76-0.94; 12-week LOR, OR = 1.12, 95% CI:1.02-1.24 and OR = 0.89, 95% CI:0.81-0.98). ROC curves showed that both phenotypic age and age gap had acceptable performance in predicting 8-week and 12-week LOR (the area under the curve (AUC) was 0.739-0.784). Conclusion: Phenotypic age is associated with LOR to biological agent in patients with CD, and has acceptable performance in predicting 8-week and 12-week LOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.